Tolerization of tumor-specific T cells despite efficient initial priming in a primary murine model of prostate cancer

Journal of Immunology

Volumn 178, Issue 3, 2007, Pages 1268-1276

  Anderson, Michael J ^a,b   Shafer Weaver, Kimberly ^a,c   Greenberg, Norman M ^d   Hurwitz, Arthur A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SUNY UPSTATE MEDICAL UNIVERSITY   (United States)

^c SAIC FREDERICK INC   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; GAMMA INTERFERON; GRANZYME B; TUMOR ANTIGEN;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; DEGRANULATION; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR VOLUME;

EID: 33846506812     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.178.3.1268     Document Type: Article

References (40)

1. Schuler, G., B. Schuler-Thumer, and R. M. Steinman. 2003. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15: 138-147.
2. Steinman, R. M., D. Hawiger, and M. C. Nussenzweig. 2003. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21: 685-711.
3. + T cells in vivo. J. Immunol. 163: 2561-2567.
4. + T cells protect against experimentally induced asthma and alter pulmonary dendritic cell phenotype and function. J. Exp. Med. 202: 1549-1561.
5. + T cells. J. Immunol. 176: 6202-6210.
6. Vicari, A. P., C. Chiodoni, C. Vaure, S. Ait-Yahia, C. Dercamp, F. Matsos, O. Reynard, C. Taverne, P. Merle, M. P. Colombo, et al. 2002. Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. J. Exp. Med. 196: 541-549.
7. Iwasaki, A., and R. Medzhitov. 2004. Toll-like receptor control of the adaptive immune responses. Nat. Immunol. 5: 987-995.
8. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393: 480-483.
9. Orabona, C., U. Grohmann, M. L. Belladonna, F. Fallarino, C. Vacca, R. Bianchi, S. Bozza, C. Volpi, B. L. Salomon, M. C. Fioretti, et al. 2004. CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86. Nat. Immunol. 5: 1134-1142.
10. Barrack, E. R. 1997. TGF β in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 31: 61-70.
11. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22: 531-562.
12. Zou, W. 2005. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5: 263-274.
13. + T lymphocytes into effector CTL. J. Immunol. 172: 6558-6567.
14. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392: 245-252.
15. Sallusto, F., and A. Lanzavecchia. 1999. Mobilizing dendritic cells for tolerance, priming, and chronic inflammation. J. Exp. Med. 189; 611-614.
16. Staveley-O'Carroll, K., E. Sotomayor, J. Montgomery, I. Borrello, L. Hwang, S. Fein, D. Pardoll, and H. Levitsky. 1998. Induction of antigen-specific T cell anergy: an early event in the course of tumor progression. Proc. Natl. Acad. Sci. USA 95: 1178-1183.
17. + CTL to cause tumor eradication. J. Immunol. 173; 6753-6759.
18. + T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J. Exp. Med. 194: 707-717.
19. + T cells. J. Exp. Med. 186: 239-245.
20. Greenberg, N. M., F. DeMayo, M. J. Finegold, D. Medina, W. D. Tilley, J. O. Aspinall, G. R. Cunha, A. A. Donjacour, R. J. Matusik, and J. M. Rosen. 1995. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 92: 3439-3443.
21. Geiger, T., L. R. Gooding, and R. A. Flavell. 1992. T-cell responsiveness to an oncogenic peripheral protein and spontaneous autoimmunity in transgenic mice. Proc. Natl. Acad. Sci. USA 89: 2985-2989.
22. Granziero, L., S. Krajewski, P. Farness, L. Yuan, M. K. Courtney, M. R. Jackson, P. A. Peterson, and A. Vitiello. 1999. Adoptive immunotherapy prevents prostate cancer in a transgenic animal model. Eur. J. Immunol. 29: 1127-1138.
23. Zheng, X., J. X. Gao, H. Zhang, T. L. Geiger, Y. Liu, and P. Zheng. 2002. Clonal deletion of simian virus 40 large T antigen-specific T cells in the transgenic adenocarcinoma of mouse prostate mice: an important role for clonal deletion in shaping the repertoire of T cells specific for antigens overexpressed in solid tumors. J. Immunol. 169: 4761-4769.
24. Ji, Q., D. Gondek, and A. A. Hurwitz. 2005. Provision of granulocyte-macrophage colony-stimulating factor converts an autoimmune response to a self-antigen into an antitumor response. J. Immunol. 175: 1456-1463.
25. Wechter, W. J., D. D. Leipold, E. D. Murray, Jr., D. Quiggle, J. D. McCracken, R. S. Barrios, and N. M. Greenberg. 2000. E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse. Cancer Res. 60: 2203-2208.
26. Sotomayor, E. M., I. Borrello, F. M. Rattis, A. G. Cuenca, J. Abrams, K. Staveley-O'Carroll, and H. I. Levitsky. 2001. Cross-presentation of tumor antigens by bone marrow-derived antigen-presenting cells is the dominant mechanism in the induction of T-cell tolerance during B-cell lymphoma progression. Blood 98: 1070-1077.
27. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264: 961-965.
28. Ochsenbein, A. F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R. M. Zinkernagel. 2001. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature 411: 1058-1064.
29. Luo, X. L., Y. Z. Yu, A. M. Liang, Y. Xie, S. X. Liu, J. Guo, W. Y. Wang, R. Z. Qi, H. Z. An, M. H. Zhang, et al. 2004. Intratumoral expression of MIP-1β induces antitumor responses in a pre-established tumor model through chemoattracting T cells and NK cells. Cell. Mol. Immunol. 1: 199-204.
30. Drake, C. G., A. D. Doody, M. A. Mihalyo, C. T. Huang, E. Kelleher, S. Ravi, E. L. Hipkiss, D. B. Flies, E. P. Kennedy, M. Long, et al. 2005. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cells 7: 239-249.
31. Carlos, C. A., H. F. Dong, O. M. Howard, J. J. Oppenheim, F. G. Hanisch, and O. J. Finn. 2005. Human tumor antigen MUC1 is chemotactic for immature dendritic cells and elicits maturation but does not promote Th1 type immunity. J. Immunol. 175: 1628-1635.
32. Oppenheim, J. J., H. F. Dong, P. Plotz, R. R. Caspi, M. Dykstra, S. Pierce, R. Martin, C. Carlos, O. Finn, O. Koul, and O. M. Howard. 2005. Autoantigens act as tissue-specific chemoattractants. J. Leukocyte Biol. 77: 854-861.
33. Tourkova, I. L., K. Yamabe, B. Foster, G. Chatta, L. Perez, G. V. Shurin, and M. R. Shurin. 2004. Murine prostate cancer inhibits both in vivo and in vitro generation of dendritic cells from bone marrow precursors. Prostate 59: 203-213.
34. + T cell tolerance through PD-1 and CTLA-4. Nat. Immunol. 6: 280-286.
35. + T cells: eradication of autologous mouse prostate cancer. Cancer Res. 65: 1761-1769.
36. Redmond, W. L., B. C. Marincek, and L. A. Sherman. 2005. Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo. J. Immunol. 174: 2046-2053.
37. + T cell effector function in SV40 T antigen transgenic mice. J. Immunol. 171: 697-707.
38. + T cells undergo peripheral tolerance. Immunity 17: 73-81.
39. Higgins, A. D., M. A. Mihalyo, and A. J. Adler. 2002. Effector CD4 cells are tolerized upon exposure to parenchymal self-antigen. J. Immunol. 169: 3622-3629.
40. Degl'Innocenti, E., M. Grioni, A. Boni, A. Camporeale, M. T. Bertilaccio, M. Freschi, A. Monno, C. Arcelloni, N. M. Greenberg, and M. Bellone. 2005. Peripheral T cell tolerance occurs early during spontaneous prostate cancer development and can be rescued by dendritic cell immunization. Eur. J. Immunol. 35: 66-75.